Literature DB >> 7513819

Comparative two-stage cancer tests of ethylene oxide, N-(2-hydroxyethyl)-N-nitrosourea and X-rays.

D Segerbäck1, C Rönnbäck, P Bierke, F Granath, L Ehrenberg.   

Abstract

Mutagenicity tests have shown that the potencies of ethylene oxide and other alkylating agents relative to that of low-LET ionising radiation are approximately the same in different biological systems. In the present study this relationship, the radiation-dose equivalence ("rad-equivalence") of doses of genotoxic chemicals, was tested for the induction of tumours in skin and lung of mice using different initiation-promotion protocols. The initiators used were X-rays, ethylene oxide and N-(2-hydroxyethyl)-N-nitrosourea (HOENU). This short-term treatment was followed by treatment with the "promoters" 12-O-tetradecanoylphorbol 13-acetate (TPA) and carbon tetrachloride. Unexpectedly, the animals treated with carbon tetrachloride did not show treatment-related liver tumours, but exhibited precocious death, mostly with lung tumours. According to estimates from in vitro tests the total in vivo dose from exposure to 400 ppm for 4 x 5 h corresponds to 700 rad-equivalents. Although still with great statistical uncertainty, this ratio is supported by the observed time-dependent frequencies of animals with papillomas (in the TPA series) and lung tumours (in the carbon tetrachloride series). Animals treated with HOENU exhibited high incidences of tumours of both these types in approximate agreement with the higher rad-equivalence of the treatments with this compound.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513819     DOI: 10.1016/0027-5107(94)90312-3

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  1 in total

Review 1.  Macromolecule adducts as biomarkers of exposure to environmental mutagens in human populations.

Authors:  L Ehrenberg; F Granath; M Törnqvist
Journal:  Environ Health Perspect       Date:  1996-05       Impact factor: 9.031

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.